Optimi Health Outlines 2027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSD; Announces Shares-for-Debt Settlement
Proposed OPTI-101 protocol amendment converts the single-arm, open-label Phase 2 trial into a randomized, double-blind Phase 2b in severe major depressive disorder, enhancing statistical power; dosing expected Q1 2027 with topline data expected in 2028